At Inotek, our focus is defining the future of eye care. We’re dedicated to using medical research and scientific innovation to restore and protect the vision of those suffering from diseases of the eye. With the groundbreaking discovery of trabodenoson, we’re ready to offer a pressure relieving solution for the eye with minimal side effects and no painful injections.
- Inotek Pharmaceuticals Corporation Announces Closing of $79.2 Million Public Offering Including Exercise in Full of Underwriters’ Option to Purchase Additional Shares Read Full Press Release
- Inotek Pharmaceuticals Corporation Announces Pricing of $68.9 Million Public Offering Read Full Press Release
- Inotek Pharmaceuticals Corporation Reports Second Quarter 2015 Financial Results and Operational Highlights Read Full Press Release
- Inotek Pharmaceuticals Phase 3 Development Plhan Conference Call Webcast Visit the Webcast Archive